Hanmi Pharm close to commercialize new once-month administration diabetes drug
Possibility to develop the once-monthly administration for a new GLP-1 diabetes drug(efpeglenatide), developed by Hanmi Pharm, has been confirmed once again.
Hanmi Pharm(CEO Kwan-soon Lee) announced that the company has revealed 9 major research cases of new long-acting diabetes drugs, which are...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
